Mirova US LLC Sells 5,150 Shares of Edwards Lifesciences Co. (NYSE:EW)

Mirova US LLC cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 0.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 860,400 shares of the medical research company’s stock after selling 5,150 shares during the quarter. Edwards Lifesciences makes up approximately 1.0% of Mirova US LLC’s holdings, making the stock its 25th largest holding. Mirova US LLC’s holdings in Edwards Lifesciences were worth $65,606,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Sequoia Financial Advisors LLC raised its holdings in Edwards Lifesciences by 11.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company’s stock worth $1,081,000 after acquiring an additional 941 shares during the last quarter. Zions Bancorporation N.A. raised its holdings in Edwards Lifesciences by 34.7% in the 1st quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company’s stock worth $204,000 after acquiring an additional 448 shares during the last quarter. Covestor Ltd raised its holdings in Edwards Lifesciences by 18.2% in the 1st quarter. Covestor Ltd now owns 1,223 shares of the medical research company’s stock worth $144,000 after acquiring an additional 188 shares during the last quarter. Mather Group LLC. raised its holdings in Edwards Lifesciences by 53.5% in the 1st quarter. Mather Group LLC. now owns 7,182 shares of the medical research company’s stock worth $846,000 after acquiring an additional 2,503 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in Edwards Lifesciences by 3.1% in the 1st quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company’s stock worth $77,173,000 after acquiring an additional 19,798 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on EW shares. Citigroup boosted their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Evercore ISI boosted their price objective on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Oppenheimer boosted their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. Finally, Stifel Nicolaus boosted their target price on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research note on Wednesday, February 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.73.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Heisz Leslie Stone sold 7,056 shares of the business’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $86.45, for a total transaction of $609,991.20. Following the completion of the sale, the director now owns 26,980 shares in the company, valued at approximately $2,332,421. The disclosure for this sale can be found here. In the last quarter, insiders sold 194,004 shares of company stock valued at $17,166,254. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock traded up $0.85 during mid-day trading on Wednesday, reaching $90.05. 2,640,500 shares of the company’s stock traded hands, compared to its average volume of 2,945,013. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The firm has a 50 day moving average price of $90.11 and a two-hundred day moving average price of $78.07. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. The firm has a market capitalization of $54.20 billion, a PE ratio of 39.16, a price-to-earnings-growth ratio of 4.42 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting the consensus estimate of $0.64. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. Edwards Lifesciences’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.64 EPS. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.